Literature DB >> 19241148

Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia.

Andrew J Holman1.   

Abstract

OBJECTIVE: Compulsivity has been associated with use of dopamine agonists used to treat Parkinson's disease (PD). Increasing use of these agents to treat fibromyalgia (FM) raises concern for this unexpected toxicity in a new group of patients. This is the first report of compulsive gambling and shopping among patients taking dopamine agonists for treatment of FM.
DESIGN: A retrospective chart review of all patients in a large, active FM research practice was used to identify compulsivity associated with dopamine agonists and describe its remission following dug withdrawal.
RESULTS: Of 3006 patients with FM treated between 2002 and 2006, 1356 had taken > or =1 dose of a dopamine agonist ( >95% pramipexole). Twenty-one (3 male, 18 female) were identified with compulsive gambling (33%), shopping (40%) or both (27%) after taking a 4.5 mg mean dose of pramipexole at bedtime for 14.4 +/- 14.9 months. Compulsivity resolved in 3-10 days for 19 of 21 patients and by 3 months for all following a monitored, compulsory tapered discontinuation over 7 days.
CONCLUSIONS: While biologic aspects of PD and FM differ considerably, compulsive gambling and shopping have become important, yet unexpected concerns related to use of dopamine agonists for patients with FM and their treating clinicians.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19241148     DOI: 10.1007/s10899-009-9123-2

Source DB:  PubMed          Journal:  J Gambl Stud        ISSN: 1050-5350


  18 in total

1.  Fibromyalgia and pramipexole: promise and precaution.

Authors:  Andrew J Holman
Journal:  J Rheumatol       Date:  2003-12       Impact factor: 4.666

Review 2.  Mesolimbic dopaminergic mechanisms and pain control.

Authors:  Patrick B Wood
Journal:  Pain       Date:  2006-01-19       Impact factor: 6.961

3.  Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis.

Authors:  Andrew H Evans; Helmut Butzkueven
Journal:  Mov Disord       Date:  2007-03-15       Impact factor: 10.338

4.  Ropinirole, open preliminary observations of a dopamine agonist for refractory fibromyalgia.

Authors:  Andrew J Holman
Journal:  J Clin Rheumatol       Date:  2003-08       Impact factor: 3.517

5.  Problematic gambling on dopamine agonists: Not such a rarity.

Authors:  Katherine A Grosset; Graeme Macphee; Guru Pal; David Stewart; Andrew Watt; Jim Davie; D G Grosset
Journal:  Mov Disord       Date:  2006-12       Impact factor: 10.338

6.  Long-term follow-up of impulse control disorders in Parkinson's disease.

Authors:  Eugenia Mamikonyan; Andrew D Siderowf; John E Duda; Marc N Potenza; Stacy Horn; Matthew B Stern; Daniel Weintraub
Journal:  Mov Disord       Date:  2008-01       Impact factor: 10.338

7.  Pathological gambling caused by drugs used to treat Parkinson disease.

Authors:  M Leann Dodd; Kevin J Klos; James H Bower; Yonas E Geda; Keith A Josephs; J Eric Ahlskog
Journal:  Arch Neurol       Date:  2005-07-11

8.  A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications.

Authors:  Andrew J Holman; Robin R Myers
Journal:  Arthritis Rheum       Date:  2005-08

9.  Predictors of impulsivity and reward seeking behavior with dopamine agonists.

Authors:  William G Ondo; Dejian Lai
Journal:  Parkinsonism Relat Disord       Date:  2007-08-16       Impact factor: 4.891

Review 10.  EULAR evidence-based recommendations for the management of fibromyalgia syndrome.

Authors:  S F Carville; L Arendt-Nielsen; S Arendt-Nielsen; H Bliddal; F Blotman; J C Branco; D Buskila; J A P Da Silva; B Danneskiold-Samsøe; F Dincer; C Henriksson; K G Henriksson; E Kosek; K Longley; G M McCarthy; S Perrot; M Puszczewicz; P Sarzi-Puttini; A Silman; M Späth; E H Choy
Journal:  Ann Rheum Dis       Date:  2007-07-20       Impact factor: 19.103

View more
  21 in total

1.  Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale.

Authors:  Daniel Weintraub; Eugenia Mamikonyan; Kimberly Papay; Judith A Shea; Sharon X Xie; Andrew Siderowf
Journal:  Mov Disord       Date:  2011-12-01       Impact factor: 10.338

2.  Decreased ventral striatal activity with impulse control disorders in Parkinson's disease.

Authors:  Hengyi Rao; Eugenia Mamikonyan; John A Detre; Andrew D Siderowf; Matthew B Stern; Marc N Potenza; Daniel Weintraub
Journal:  Mov Disord       Date:  2010-08-15       Impact factor: 10.338

3.  Effects of acute pramipexole on male rats' preference for gambling-like rewards II.

Authors:  Patrick S Johnson; Gregory J Madden; Jeffrey S Stein
Journal:  Exp Clin Psychopharmacol       Date:  2012-01-30       Impact factor: 3.157

4.  Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study.

Authors:  Daniel Weintraub; Kimberly Papay; Andrew Siderowf
Journal:  Neurology       Date:  2013-01-08       Impact factor: 9.910

5.  Effects of pramipexole on the reinforcing effectiveness of stimuli that were previously paired with cocaine reinforcement in rats.

Authors:  Gregory T Collins; Alyssa R Cunningham; Jianyong Chen; Shaomeng Wang; Amy H Newman; James H Woods
Journal:  Psychopharmacology (Berl)       Date:  2011-06-24       Impact factor: 4.530

6.  Effects of acute pramipexole on preference for gambling-like schedules of reinforcement in rats.

Authors:  Patrick S Johnson; Gregory J Madden; Adam T Brewer; Jonathan W Pinkston; Stephen C Fowler
Journal:  Psychopharmacology (Berl)       Date:  2010-09-04       Impact factor: 4.530

7.  Influence of conditioned reinforcement on the response-maintaining effects of quinpirole in rats.

Authors:  Gregory T Collins; James H Woods
Journal:  Behav Pharmacol       Date:  2009-09       Impact factor: 2.293

8.  Determinants of conditioned reinforcing effectiveness: Dopamine D2-like receptor agonist-stimulated responding for cocaine-associated stimuli.

Authors:  Gregory T Collins; Charles P France
Journal:  Eur J Pharmacol       Date:  2015-11-21       Impact factor: 4.432

Review 9.  Dopamine agonist withdrawal syndrome: implications for patient care.

Authors:  Melissa J Nirenberg
Journal:  Drugs Aging       Date:  2013-08       Impact factor: 3.923

10.  Uncertainty about mapping future actions into rewards may underlie performance on multiple measures of impulsivity in behavioral addiction: evidence from Parkinson's disease.

Authors:  Bruno B Averbeck; Atbin Djamshidian; Sean S O'Sullivan; Charlotte R Housden; Jonathan P Roiser; Andrew J Lees
Journal:  Behav Neurosci       Date:  2013-04       Impact factor: 1.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.